Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
7 Biotech Stocks to Get In Now Before Investors Catch On
02:50am, Monday, 23'rd Oct 2023
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
CRISPR Therapeutics Stock: Bull vs. Bear
06:45pm, Saturday, 21'st Oct 2023
The potential for CRISPR Therapeutics' pipeline is tremendous. However, an expected product approval may not offer the stock a huge lift.
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
05:00am, Saturday, 21'st Oct 2023
Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.
3 Gene Editing Stocks to Generate Super-Charged Gains
11:05am, Wednesday, 18'th Oct 2023
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia,
This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street
05:30am, Monday, 16'th Oct 2023
Superstar investor Wood looks for innovators whose products could be game changers down the road. She goes for companies that are undervalued today considering their long-term potential.
2 Growth Stocks That Could Double Your Money, According to Wall Street
06:47am, Sunday, 15'th Oct 2023
There are a couple of stocks in the healthcare sector that could climb more than 100%, according to consensus estimates from Wall Street analysts. Analysts expecting CRISPR Therapeutics to launch its
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
12:20pm, Saturday, 14'th Oct 2023
Gene-editing stocks have gotten pummeled by the market's growing aversion to risk. Nonetheless, the field has made substantial progress of late.
Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock
12:01pm, Friday, 13'th Oct 2023
Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.
BEAM Focuses on Developing Gene Drug for Growth
11:16am, Tuesday, 10'th Oct 2023
While BEAM's pipeline candidates are in early-stage clinical studies, their development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.
Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?
05:30am, Tuesday, 10'th Oct 2023
Cathie Wood is betting on CRISPR Therapeutics' ability to cure certain diseases through its gene editing techniques. The company is about to reach an important moment -- one that could lead to blockbu
Nobel for mRNA: Which other biotech stocks might be overlooked?
08:33am, Friday, 06'th Oct 2023
Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA v
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
05:00pm, Tuesday, 03'rd Oct 2023
In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three c
Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics
10:00am, Monday, 02'nd Oct 2023
Editas Medicine and CRISPR Therapeutics are racing towards the same market. It looks like Bluebird Bio is going to be the player to beat in that market.
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
10:07pm, Sunday, 01'st Oct 2023
These three companies have a proven ability to develop innovative products in the healthcare field. All three have performed poorly on the market over the past year, but their prospects remain intact.
3 Cathie Wood Stocks Set to Explode Higher
07:45pm, Sunday, 01'st Oct 2023
Love her or loathe her, Cathie Wood's magnetic pull on the investment world remains undiminished. Wood has uniquely curated portfolios brimming with disruptive tech firms and ambitious start-ups offer
